Preliminary DMT therapy data will guide the decision to initiate a phase 2 trial in the U.S. in early 2024. The post Cybin Lands Key U.S....
Reset Pharma is specifically honing in on the plight of cancer patients. The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer...
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder...
Harm reduction and integration for people choosing to use psychedelics is important for both safety and maximization of benefits. Simply put, psychedelic...
The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs. The post Cybin Granted U.S. Patent for 5-MeO-DMT appeared...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-based Small...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed. The post News...
Many experts have been predicting some big mergers and acquisitions in the psychedelic industry. Well, it looks like they were spot on. This week has...
Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome Filament Health...
Its parent company, Otsuka Holdings Co. Ltd., has a market cap hovering above $20 million. The post Otsuka Pharmaceutical to Acquire Mindset Pharma for...